PharmEasy-Owned Thyrocare To Exit Radiology, Sell Nueclear Healthcare For ₹141 Cr

by · Inc42

SUMMARY

  • Thyrocare has approved the sale of its entire stake in Nueclear Healthcare to Trovera Healthcare for approximately ₹141.4 Cr.
  • The divestment will mark Thyrocare’s exit from the investment-intensive radiology business and allow it to focus on its core pathology operations.
  • Thyrocare will receive approximately ₹81.9 Cr in cash and Trovera CCPS worth ₹59.5 Cr as part of the transaction.